Research progress in pharmacological effects of Erigeron breviscapus and its active ingredients for treatment of Alzheimer's disease / 中国中药杂志
China Journal of Chinese Materia Medica
;
(24): 5650-5657, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-878825
ABSTRACT
Alzheimer's disease(AD) is a neurodegenerative disease that has no effective drug to cure it. Studies in several AD models have shown that Erigeron breviscapus and its active ingredients(scutellarin and caffeoylquinic acid) could improve/enhance the learning and memory ability, and the mechanisms are associated with inhibiting amyloid β(Aβ) production, aggregation, fibrosis and Aβ neurotoxicity toxicity, regulating cholinergic nervous system, inhibiting oxidative stress and inflammation, inhibiting tau hyperphosphorylation, improving mitochondrial function, and resisting neuronal apoptosis. This article systematically reviewed the research progress of E. breviscapus and its active ingredients for treatment of AD in AD models, in the expectation of providing references for further development of E. breviscapus's medicinal potential.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Péptidos beta-Amiloides
/
Enfermedades Neurodegenerativas
/
Erigeron
/
Enfermedad de Alzheimer
Tipo de estudio:
Revisiones Sistemáticas Evaluadas
Límite:
Humanos
Idioma:
Chino
Revista:
China Journal of Chinese Materia Medica
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS